Sareum
  • Home
  • About us
    • What we do
    • How we work
    • Our strategy
    • History
    • Management
  • Research & Development
    • Overview
    • Autoimmune - TYK2/JAK1 kinases
    • Cancer - TYK2/JAK1 kinases
    • TYK2/JAK1 - Viral Infections
    • Cancer – Chk1 kinase
    • Other programmes
    • Drug discovery
    • Discovery platform
  • Partners
    • Overview
  • Investors
    • Document centre
    • Corporate governance
    • Share price, RNS and Research
    • AIM rule 26
    • Advisers
  • News
    • Press releases
    • News archive
    • Events
    • Patents and publications
    • Presentations and press
  • Contact
  • Sitemap
  • Terms
  • Accessibility
  • Privacy and Cookies
 

Sitemap

  • Home
  • About us
    • What we do
    • How we work
    • Our strategy
    • History
    • Management
  • Research & Development
    • Overview
    • Autoimmune - TYK2/JAK1 kinases
    • Cancer - TYK2/JAK1 kinases
    • TYK2/JAK1 - Viral Infections
    • Cancer – Chk1 kinase
    • Other programmes
    • Drug discovery
    • Discovery platform
  • Partners
    • Overview
  • Investors
    • Document centre
    • Corporate governance
    • Share price, RNS and Research
    • AIM rule 26
    • Advisers
  • News
    • Press releases
    • News archive
    • Events
    • Patents and publications
    • Presentations and press
  • Contact
  • @Sareumplc Latest tweet

    via @
    View more

Contact

Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom


tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
email_white.png

Site search

Search

Find us online

Proactive Investors logo

Downloads

Full-year Results 2022       ¦

Annual Report 2022           ¦

Annual Report 2022      

 

© Sareum Holdings PLC

Site by Design Portfolio

  • Sitemap
  • Terms
  • Accessibility
  • Privacy and Cookies